SCHEMBL375222

SCHEMBL375222

FC(F)(F)Oc1cccc(CNC2CCOCC2)c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 3/20 0.61
PRMT6 Q96LA8 2/20 0.61
ALDH1A1 P00352 1/20 0.52
BCHE P06276 2/20 0.49
ACHE P22303 2/20 0.49
BACE1 P56817 2/20 0.49
PRMT5 O14744 1/20 0.48
WDR77 Q9BQA1 1/20 0.48
GLS O94925 1/20 0.47
MCHR1 Q99705 1/20 0.46
PIM1 P11309 4/20 0.45
RIPK2 O43353 1/20 0.44
MAPK14 Q16539 1/20 0.44
KDM5A P29375 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
EPHX1 P07099 1/20 0.43
KCNN3 Q9UGI6 1/20 0.42
MAP4K4 O95819 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2466378 0.90 CARM1 (0.68) CARM1PRMT6ALDH1A1BCHEACHE
SCHEMBL29456931 0.90 CARM1 (0.68) CARM1PRMT6ALDH1A1BCHEACHE
SCHEMBL374836 0.87 CARM1 (0.51) CARM1PRMT6GLSPIM1EPHX1
SCHEMBL8217923 0.86 CARM1 (0.59) CARM1PRMT6ALDH1A1BCHEACHE
SCHEMBL1006996 0.84 CARM1 (0.61) CARM1PRMT6ALDH1A1BCHEACHE
SCHEMBL374999 0.84 ALDH1A1 (0.52) CARM1PRMT6ALDH1A1PRMT5WDR77
SCHEMBL8212416 0.84 CARM1 (0.56) CARM1PRMT6ALDH1A1BCHEACHE
SCHEMBL374832 0.83 BCHE (0.60) CARM1PRMT6BCHEACHEBACE1
SCHEMBL4575142 0.83 CARM1 (0.60) CARM1PRMT6ALDH1A1BCHEACHE
SCHEMBL375093 0.82 ALDH1A1 (0.76) ALDH1A1PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
EP-2409976-A1 GLYCINE TRANSPORTER INHIBITOR Taisho Pharmaceutical Co., Ltd. (JP) 2012-01-25 EP disclosed
EP-2409976-A1 GLYCINE TRANSPORTER INHIBITOR Taisho Pharmaceutical Co., Ltd. (JP) 2012-01-25 EP disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES SLC18A2, SLC1A2, SLC6A1 CARM1 2663/4885PRMT6 2112/4885ALDH1A1 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.